Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
74.51 USD | -0.36% | +0.99% | +4.28% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The firm trades with high earnings multiples: 22.64 times its 2024 earnings per share.
- With an enterprise value anticipated at 4.37 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.28% | 17.39B | B+ | ||
+9.48% | 222B | B | ||
+13.72% | 195B | B- | ||
+23.79% | 148B | B- | ||
+33.39% | 113B | A- | ||
+4.75% | 66.45B | A- | ||
+15.59% | 53.11B | B+ | ||
+3.16% | 50.03B | B+ | ||
-4.35% | 38.8B | A | ||
-1.27% | 34.85B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HOLX Stock
- Ratings Hologic, Inc.